GO:0141217 glycoRNA biosynthetic process Guide

GO:0141217, glycoRNA biosynthetic process, is a biological process defined as the posttranscriptional addition of a carbohydrate or carbohydrate derivative unit to residues in an RNA molecule, generating glycoRNAs that consist of RNAs modified with secretory N-glycans presented on the cell surface. This term captures a recently recognized layer of RNA biology in which RNA molecules are not only chemically modified on nucleobases or ribose but also carry N-glycan moieties that route them to the cell surface. The discovery that small RNAs are modified with N-glycans and displayed on the surface of living cells fundamentally expanded the known repertoire of RNA modifications and cell-surface molecules. Understanding glycoRNA biosynthetic process matters because it connects RNA metabolism, glycosylation machinery, and cell-surface recognition. The identification of acp3U as an attachment site for N-glycans in glycoRNA provided a molecular explanation for how glycans are covalently linked to RNA. Furthermore, glycoRNAs interact with RNA-binding proteins to form domains on the cell surface that mediate cell-penetrating peptide entry, indicating that these molecules participate in extracellular interactions and cargo uptake. Functionally, RNA N-glycosylation enables immune evasion and homeostatic efferocytosis, linking glycoRNA biosynthesis to immune recognition and clearance of dying cells. Cell surface RNAs, including glycoRNAs, also control neutrophil recruitment, underscoring their importance in immune cell trafficking. As an emerging field, glycoRNA research is moving from unknown unknowns to known unknowns, with growing interest in glycoRNAs as drug targets and in altered glycosylation in cancer. Researchers studying glycoRNA biosynthetic process therefore need robust tools to perturb candidate genes, detect glycoRNA species, and dissect their functions in health and disease.

In our own words, GO:0141217 (glycoRNA biosynthetic process) refers to the cellular process in which a carbohydrate or carbohydrate derivative unit is added after transcription to residues within an RNA molecule, producing glycoRNAs. These glycoRNAs are characterized by secretory N-glycans that are presented on the cell surface. The process includes the enzymatic attachment of N-glycans to specific modified RNA bases, such as acp3U, and the subsequent presentation of the resulting glycoRNA at the plasma membrane. Synonyms for this term include glycoRNA biosynthesis and RNA glycosylation.

GlycoRNA biosynthetic process is important because it defines a newly discovered mechanism by which RNA molecules acquire N-glycan modifications and become cell-surface-displayed glycoconjugates, thereby expanding the functional repertoire of RNA beyond classical roles in translation and gene regulation. This process links RNA modification chemistry, glycosylation pathways, and cell-surface biology, and it has been implicated in immune evasion, efferocytosis, neutrophil recruitment, and interactions with cell-penetrating peptides. As the field matures, glycoRNAs are being explored as emerging drug targets and as components of altered glycosylation in cancer, making the biosynthetic process a focal point for therapeutic and diagnostic research.

The following genes and proteins have been implicated in glycoRNA biosynthetic process, its regulation, or its functional consequences, based on the verified literature.

Regulation of glycoRNA biosynthetic process is an emerging area. The process is posttranscriptional and depends on the availability of secretory N-glycans and appropriate RNA acceptor sites such as acp3U. Cell-surface presentation and domain formation with RNA-binding proteins suggest that trafficking and protein interactions regulate glycoRNA function. Immune-related outcomes, including immune evasion and efferocytosis, indicate that glycoRNA biosynthesis is integrated with immune signaling. Cell surface RNAs controlling neutrophil recruitment further support regulation in inflammatory contexts. However, specific transcriptional or signaling regulators of the pathway remain to be fully defined, and the field is characterized by known unknowns.

Altered glycosylation is a hallmark of cancer with molecular functions and therapeutic potential, and glycoRNA biosynthetic process represents a newly recognized dimension of glycosylation biology. Because glycoRNAs carry N-glycans and are displayed on the cell surface, changes in the pathway could contribute to cancer cell surface phenotypes and immune interactions. GlycoRNAs are also being considered as emerging drug targets, suggesting therapeutic opportunities in oncology and beyond.

RNA N-glycosylation enables immune evasion and homeostatic efferocytosis, directly linking glycoRNA biosynthetic process to immune recognition and clearance of apoptotic cells. These findings imply that dysregulation of glycoRNA biosynthesis could affect immune surveillance and inflammatory resolution. Cell surface RNAs, including glycoRNAs, also control neutrophil recruitment, further connecting the pathway to immune cell trafficking.

GlycoRNAs form cell-surface domains with RNA-binding proteins that mediate cell-penetrating peptide entry, a process relevant to delivery of extracellular cargo and potential pathogen or therapeutic interactions. Cell surface RNA-dependent neutrophil recruitment highlights roles in inflammation. Together, these observations suggest that glycoRNA biosynthetic process may influence host-pathogen interactions and inflammatory responses, although specific disease mechanisms require further study.

GlycoRNAs were originally detected as small RNAs modified with N-glycans and displayed on the surface of living cells, establishing methods for their identification. The identification of acp3U as an N-glycan attachment site provides a chemical target for detection and validation. Researchers can use these approaches to confirm whether a gene perturbation alters glycoRNA biosynthetic process.

Because glycoRNAs form domains on the cell surface with RNA-binding proteins, imaging approaches are essential to study their spatial organization and function. Tagged knock-in models can be used to visualize specific components at the plasma membrane. Such methods help link glycoRNA biosynthetic process to cell-penetrating peptide entry and other surface interactions.

RNA N-glycosylation enables immune evasion and homeostatic efferocytosis, so functional assays measuring immune recognition and clearance are key to studying the pathway. Cell surface RNA-dependent neutrophil recruitment can be assessed in immune cell models. These assays connect glycoRNA biosynthetic process to physiologically relevant immune outcomes.

Altered glycosylation in cancer can be profiled to identify disease-relevant changes in glycoRNA pathways. GlycoRNAs as emerging drug targets motivate profiling and pharmacological studies. Combining glycosylation profiling with genetic perturbation can reveal how glycoRNA biosynthetic process contributes to cancer phenotypes.

Researchers studying glycoRNA biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in RNA glycosylation, cell-surface presentation, or downstream immune and cancer phenotypes. Rigorous causal testing requires precise genetic models, including knockout, point-mutation, knock-in, and overexpression cell lines, as well as screening and bioinformatics support to interpret complex glycoRNA datasets.

GO:0141217 (glycoRNA biosynthetic process) captures a newly discovered biological process in which RNAs are posttranscriptionally modified with secretory N-glycans and displayed on the cell surface. The identification of acp3U as an N-glycan attachment site, the formation of cell-surface glycoRNA-protein domains, and roles in immune evasion, efferocytosis, and neutrophil recruitment highlight the broad significance of this pathway. As the field advances from unknown unknowns to known unknowns, glycoRNAs are emerging as drug targets and as contributors to altered glycosylation in cancer. For researchers, precise genetic models are essential to establish causality and mechanism. CRISPR knockout, point-mutation, knock-in, and overexpression cell models, together with CRISPR library screening and bioinformatics, provide a robust toolkit to dissect glycoRNA biosynthetic process and translate its biology into therapeutic insights.